The FDA lifts a partial hold on Mersana's top drug -- and then its shares crater
Mersana $MRSN and the FDA have come up with a newly revised development program for the biotech’s lead drug just a couple months after a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
